Randomized Trial of Apixaban vs Dose Adjusted Warfarin in Reducing Rate of Cognitive Function Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Non-valvular Atrial Fibrillation Patients With CHA2DS2-VaSc Score = 2
Phase: PHASE3
Conditions: Atrial Fibrillation
Sponsor: Mayo Clinic

 
 
Randomized trial of Apixaban vs dose 
adjusted Warfarin in reducing rate of 
cognitive function decline, silent cerebral 
infarcts and cerebral microbleeds in non-
valvular atrial fibrillation patients with 
CHA2DS2-VaSc score ≥2. 
 
 
NCT03839355 
 
12/18/2018 

Randomized trial of Apixaban vs dose adjusted Warfarin in reducing rate of cognitive function decline, 
silent cerebral infarcts and cerebral microbleeds in non-valvular atrial fibrillation patients with 
CHA2DS2-VaSc score ≥2. 
 
Protocol Number: 7.0 
 
Principal Investigator:  
Malini Madhavan, MBBS 
Samuel J. Asirvatham, MD 
Department of Cardiology, Mayo Clinic, Rochester 
Co-Investigators: 
Kejal Kantarci, MD 
Department of Radiology, Mayo Clinic, Rochester 
Ronald Petersen, MD 
Department of Neurology, Mayo Clinic, Rochester 
 
Funded by: BMS/Pfizer 
Version Number:  v.2.0 
18 December 2018 
 
 
Summary of Changes from Previous Version: 
Affected 
Section(s) 
Summary of Revisions Made 
Rationale 
 
 
 
 
 
 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
STATEMENT OF COMPLIANCE 
 
The trial will be carried out in accordance with International Conference on Harmonisation Good Clinical 
Practice (ICH GCP) and the following:  
 
• 
United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR 
Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812)  
 
Mayo Clinic investigators and clinical trial site staff who are responsible for the conduct, 
management, or oversight of this clinical trial have completed Human Subjects Protection and 
ICH GCP Training. 
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will 
be submitted to the Institutional Review Board (IRB) for review and approval.  Approval of both 
the protocol and the consent form must be obtained before any participant is enrolled.  Any 
amendment to the protocol will require review and approval by the IRB before the changes are 
implemented to the study.  In addition, all changes to the consent form will be IRB-approved; a 
determination will be made regarding whether a new consent needs to be obtained from 
participants who provided consent, using a previously approved consent form. 
 
 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
 
1 
 
PROTOCOL SUMMARY 
1.1 
SYNOPSIS  
Title: 
Randomized trial of Apixaban vs dose adjusted Warfarin in reducing rate of 
cognitive function decline, silent cerebral infarcts and cerebral 
microbleeds in non-valvular atrial fibrillation (NVAF) patients with 
CHA2DS2-VaSc score ≥2. 
 
Study Description: 
This study is a randomized clinical trial of patients with AF, whose 
CHA2DS2-VaSc score ≥2, it will compare Apixaban vs dose adjusted 
warfarin on the rate of cognitive function decline, silent cerebral infarction 
and cerebral microbleed. Our hypothesis is that, anticoagulation with 
Apixaban reduces the rate of decline in cognitive function, when 
compared to Warfarin and that Apixaban reduces cognitive decline by 
reducing the rate of new cerebral infarction and cerebral microbleeds 
detected by cerebral MRI compared to warfarin.  
 
Objectives: 
 
Primary Objective:  Assess the difference in decline in cognitive function 
using standardized neurocognitive assessment in AF patients treated with 
Apixaban vs Warfarin. 
 
Secondary Objectives: Assess the difference in incident mild cognitive 
impairment or dementia in NVAF patients treated with Apixaban vs 
Warfarin. Assess the difference in development of new silent cerebral 
infarcts and cerebral microbleeds on brain magnetic resonance imaging 
(MRI) in NVAF treated with Apixaban vs Warfarin.  
 
Endpoints: 
Primary Endpoint: The individual cognitive domain and global cognitive 
function score in NVAF patients treated with Apixaban vs Warfarin 
Secondary Endpoints: (1) New mild cognitive impairment or dementia; (2) 
new cerebral infarcts on brain MRI and (3) new cerebral microbleeds on 
brain MRI in NVAF treated with Apixaban vs Warfarin.  
 
Study Population: 
Patients (male and female over the age of 60 years) diagnosed with NVAF 
over the age of 60 years with a CHA2DS2-VASc score ≥2, who have never 
been treated with Apixaban , or prior treatment with Apixaban <1 month.  
 
Phase: 
3 
 
Description of 
Sites/Facilities Enrolling 
Participants: 
Mayo Clinic, Rochester    
 
Description of Study 
Intervention: 
 
Apixaban 
5 mg twice daily unless patient has any 2 of the following: Age ≥80 years, 
body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, then reduce dose to 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
2.5 mg twice daily. 
 
Warfarin 
Dose adjusted to maintain INR between 2 – 3. Dose adjustment will be 
performed using a standardized nomogram at an anti-coagulation clinic or 
by treating physician. 
 
Study Duration: 
36 months 
 
Participant Duration: 
24 months 
 
 
 
 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
1.2 
SCHEMA 
 
 
 
Prior to  
Enrollment 
 
 
 
 Visit 1 
 
 
 
 
 
 
 
 
 
 
Visit 2 
1 year 
 
 
 
 
 
Visit 3 
2 year 
 
 
 
Screen potential participants by inclusion and exclusion criteria. Contact potential 
participants by telephone or mailed letter. Or approach at already scheduled clinical 
appointment 
Obtain informed consent. Obtain history, document, serum creatinine. 
Perform baseline measurements 
1. Assessment of cognitive function (before or within 1 month of randomization) 
2. MRI (before randomization) 
 
Follow-up measurements of study endpoints and safety (±90 days) 
 
1. Assessment of cognitive function 
Final Measurements (±90 days) 
1. Assessment of cognitive 
function 
2.  MRI 
 
Warfarin 
N=140 
Apixaban 
N=140 
Randomize (N=280) 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
2 
 
INTRODUCTION 
 
2.1 
STUDY RATIONALE  
 
The Problem 
There is a vast growing body of evidence linking atrial fibrillation (AF) with an increased risk for cognitive 
impairment (from mild to severe dementia) independent of clinical stroke history 1-3. Further, it is 
described that AF can lead to development of dementia at an earlier age and a more rapid decline in 
cognitive function 4. Both AF and cognitive impairment have profound effects and burdens on health 
care systems through increasing cost and complexity of medical care associated with these diagnoses 5, 6. 
It is crucial therefore to identify ways to reduce the global burden of cognitive impairment observed in 
patients with AF. 
 
The Mechanism  
The relationship between AF and cognitive impairment is intricate and likely driven by two major 
mechanisms; cerebral infarction (both overt and subclinical) and cerebral micro-bleeds (CMBs). 
Anticoagulation can reduce the risk of cerebral infarction but this may be offset by the increased risk of 
CMBs. 
 
The Solution  
Therefore, there is a need for an anticoagulant in the treatment of AF that can not only reduce the 
incidence of clinical stroke but also silent cerebral infarcts with the added benefit of reducing the risk of 
CMBs and overt intracranial hemorrhage. By identifying an anticoagulant that can achieve these end 
points, there is a potential to reduce the risk of cognitive decline in patients with NVAF. 
 
 
2.2 
BACKGROUND  
 
Atrial Fibrillation and Cognitive Decline/Dementia – a major association 
Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide, with an estimated prevalence 
of 33.5 million7. 7. It is reported that 3.8 percent of people 60 years of age and older and 9.0 percent of 
those 80 years of age and older have atrial fibrillation 8. Similarly to AF, cognitive impairment and 
dementia plots an increasing prevalence with age and share many risk factors such as advanced age, 
hypertension and diabetes 9-11. The first proposal of an association between AF and dementia was 
20 years ago when the Rotterdam Study described the existence of a positive association between AF 
and dementia, with a > 2-fold increased risk for dementia.12 Since then there has been a growing body of 
strong and reproducible evidence linking AF with an increased risk of cognitive impairment and 
dementia independent of shared risk factors and stroke.1-3 AF increases the risk of cognitive impairment 
by 40% in those without stroke and doubles it in patients with history of stroke.13 AF also leads to 
development of dementia at an earlier age and a more rapid decline in cognitive function 4. AF and 
cognitive impairment both have profound effects and burdens on health care systems through 
increasing cost and complexity of medical care associated with these diagnoses 5, 6. It is therefore crucial 
to identify ways to reduce the global burden of cognitive impairment observed in patients with AF. 
Mechanisms Underlying the Association between Atrial Fibrillation and Dementia 
The mechanisms for the association between AF and cognitive decline are intricate and multifactorial. 
Potential mechanisms include linking atrial ﬁbrillation and cognitive impairment/dementia include 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
cerebral hypoperfusion, vascular inﬂammation, cerebral vascular disease, thromboembolism and brain 
atrophy.  Of particular interest and felt to play a major role is cerebral infraction, both overt and 
subclinical.  
 
Cerebral infarctions occur due to systemic embolism as a consequence of AF and are associated with 
significant risk of dementia in the general population and in patients with AF.14-16 While overt stroke is 
one of the most feared sequela of AF, subclinical cerebral ischemic lesions (as detected by magnetic 
resonance imaging [MRI]) have been reported in up to 90% of participants with AF. These lesions have 
been consistently associated with an increased rate of dementia and decline in global cognitive 
function.17 
 
Similarly, CMBs also contribute towards the association of AF and dementia or cognitive decline. CMBs 
are asymptomatic cerebral hemorrhages detected by MRI that often occur in association with cerebral 
amyloid angiopathy. They increase the risk for intracranial hemorrhage (particular in the setting of 
anticoagulation for AF 18, 19 and are associated with worse cognitive outcomes. 20-22 Remarkably, in AF 
patients that manifest cognitive impairment, there is often a significant presence of cerebral micro 
bleeds detected on brain MRI In patients 14, 23-25.   
 
Role of Anticoagulation  
The central role of cerebral infractions and CMBs in the association between AF and dementia suggests 
that anticoagulation could be a key player in the association. It is plausible that effective anticoagulation 
of AF-patients could reduce the risk of cognitive impairment by reducing the risk of cerebral infarction. 
Anticoagulation however also increases the risk for macro- and micro- bleeds in the brain, which in turn 
may increase the risk of cognitive dysfunction. Hence an ideal anticoagulant should reduce the incidence 
of cerebral infarcts without significantly increasing the risk of cerebral hemorrhage.  
 
Some observational studies have investigated the impact of various anticoagulation strategies for AF 
treatment on dementia. Warfarin, as the most common prescribed anticoagulant, was the initial focus 
of many studies and it was shown that warfarin could reduce the incidence of dementia in patients with 
AF.26 However, it has a narrow therapeutic window and its efficacy in reducing dementia I contingent on 
maintaining a high time in therapeutic range; rates of incident dementia were nearly 2-fold higher in the 
subjects with the poorest anticoagulation maintenance compared to those with the highest 
anticoagulation time in therapeutic range. We also recently published further supporting evidence with 
the addition that supra-therapeutic INRs on warfarin increase the risk for dementia compared to 
therapeutic INR.27 While sub-therapeutic INR increases risk of cerebral embolism, supra-therapeutic INR 
can increase cerebral microbleeds and intracranial hemorrhage. Patients with an INR>3 more than 25% 
of the time are 2.4 times more likely to develop dementia28. While supratherapeutic INR is a risk for 
CMB, it has also been highlighted that patients in general who are treated with vitamin K antagonists 
(VKA) were more likely to have CMBs18. Hence it is becoming increasingly clear that warfarin may not be 
the ideal anticoagulant to prevent the devastating complication of cognitive impairment.  
 
Apixaban, a direct oral anticoagulant, may be alterative for anticoagulation to reduce the risk of 
dementia. The ARISTOTLE trial has demonstrated that Apixaban is non-inferior and infact superior to 
warfarin in reducing the incidence of clinical stroke in AF.29 Compared to warfarin, Apixaban may 
provide more steady state of anticoagulation. Further, the incidence of intracranial hemorrhage was 
significantly lower in Apixaban treated patients compared to warfarin, which was a striking finding of the 
ARISTOTLE trial.29 While it is clear that Apixaban can reduce the risk of stroke it also remarkably does not 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
seem to increase the prevalence of CMB in patients with atrial fibrillation, compared with aspirin30. 
Therefore, as suggested by a recent retrospective observational analysis 31,  Apixaban could potentially 
be associated with a reduced risk of cognitive impairment compared to warfarin. 
 
 
2.3 
RISK/BENEFIT ASSESSMENT   
 
2.3.1 KNOWN POTENTIAL RISKS  
Immediate Risk 
 
Physical  
Physical immediate risks will be largely related to the anticoagulants that will be administered, whether 
that is warfarin or Apixaban. These risks are summarized below. It is notable that these drugs will be 
prescribed according to existing guidelines from the American Heart Association. Drug administration 
will be in accordance with FDA approved guidelines and drug package insert. 
 
• 
Apixaban (ELIQUIS) 
The major risk for this drug is increased risk of bleeding which can be serious and potentially 
fatal. The safety of Apixaban has been evaluated in the ARISTOTLE and AVERROES studies and 
includes 11,284 patients exposed to ELIQUIS 5 mg twice daily and 602 patients exposed to 
ELIQUIS 2.5 mg twice daily. The duration of ELIQUIS exposure was >12 months for 9375 patients 
and >24 months for 3369 patients in the two studies. In ARISTOTLE, the mean duration of 
exposure was 89 weeks (>15,000 patient-years). In AVERROES, the mean duration of exposure 
was approximately 59 weeks (>3000 patient-years). The most common reason for treatment 
discontinuation in both studies was for bleeding-related adverse reactions; in ARISTOTLE this 
occurred in 1.7% and 2.5% of patients treated with Apixaban and warfarin, respectively, and in 
AVERROES, in 1.5% and 1.3% on Apixaban and aspirin, respectively. Further, concomitant use of 
drugs affecting hemostasis increases the risk of bleeding. These include aspirin and other 
antiplatelet agents, other anticoagulants, heparin, thrombolytic agents, selective serotonin 
reuptake inhibitors, serotonin norepinephrine reuptake inhibitor, and nonsteroidal anti-
inflammatory drugs (NSAIDs). Additionally, hypersensitivity reactions (including drug 
hypersensitivity, such as skin rash, and anaphylactic reactions, such as allergic edema) and 
syncope were reported in <1% of patients receiving Apixaban. Lastly, should any discontinue 
Apixaban in the absence of adequate alternative anticoagulation there is an increases risk of 
thrombotic events. Therefore if Apixaban must be discontinued for a reason other than 
pathological bleeding, coverage with another anticoagulant will be considered. This is based on 
the FDA boxed warning that accompanies the drug that is stated as follows: 
“Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of 
thrombotic events. To reduce this risk, consider coverage with another anticoagulant if ELIQUIS 
is discontinued for a reason other than pathological bleeding or completion of a course of 
therapy.” 
 
 
• 
Warfarin 
Warfarin can cause major or fatal bleeding with bleeding more likely to occur within the first 
month. Necrosis and/or gangrene of skin and other tissues is an uncommon but serious risk 
(<0.1%). In general, the risk of major internal bleeding is about 1 to 3 percent per year; patients 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
who have tolerated warfarin well for at least six months and are on a stable dose of warfarin 
usually have a risk for major internal bleeding that is closer to 1 percent per year. 
 
Psychological, social, legal, and economic 
We do not foresee any risks in this regard. 
 
Long range Risk 
Physical  
As discussed above major long range risk will be largely related to the anticoagulants that will be 
administered, whether that is warfarin or Apixaban. Both Apixaban and warfarin will be prescribed only 
in patients who meet American Heart Association guidelines for treatment with an oral anticoagulant for 
stroke prevention in NVAF. Hence the treating physician has determined based on existing literature and 
guidelines that the benefit of anticoagulation in terms of stroke prevention outweighs the risk of 
bleeding in these patients. 
 
• 
Apixaban (ELIQUIS) 
Risks discussed above in immediate risk.  
 
• 
Warfarin 
Risks discussed above in immediate risk.  
 
Economic 
During the trial the patient will receive Apixaban (if randomized to the Apixaban arm) drug therapy free 
of charge. Warfarin and its monitoring will not be paid for by the study since it is considered the 
standard of care. The cost of medical care or other costs related to any adverse events will not be 
covered by the study. Following completion of an individual’s participation in the trial (due to end of 
follow-up, or withdrawal from the study), the cost of all medications and related monitoring will be 
borne by the patient and/or their insurance – these costs will not be covered by the study.  
 
Psychological, social, and legal 
The psychological risk of the study include possible minor discomfort or anxiety in the setting of 
neuropsychologic testing or during brain MR imaging. 
 
 
2.3.2 KNOWN POTENTIAL BENEFITS  
 
Immediate potential benefits 
 
Physical  
Physical immediate benefits will largely be related to the reduction in thromboembolism risk whether 
that is warfarin or Apixaban. All patients in the trial would quality or warrant anticoagulation to reduce 
their risk according to established guidelines. 
 
• 
Apixaban (ELIQUIS) 
The major benefit of this drug is the reduction in risk of thromboembolism. The ARISTOTLE trial 
showed a significant reduction in stroke or systemic embolization when compared to warfarin 
(1.27 % vs 1.60%/year, respectively; Hazard ratio, 0.79, P-value=0.01). Further treatment with 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
Apixaban in this trial resulted in a significantly lower rate of all-cause death (p = 0.046) than did 
treatment with warfarin, primarily because of a reduction in cardiovascular death, particularly 
stroke deaths. The AVERROES trial showed a greater benefit compared to aspirin (1.62 % vs 
3.63%/year, respectively; hazard ratio 0.45, P-value< 0.0001) in patients thought not to be 
candidates for warfarin therapy. 
 
• 
Warfarin 
In five prospective, randomized, controlled clinical trials involving 3711 patients with non-
rheumatic AF, warfarin significantly reduced the risk of systemic thromboembolism including 
stroke. The risk reduction ranged from 60% to 86% in all except one trial (CAFA: 45%), which was 
stopped early due to published positive results from two of these trials. 
 
Psychological 
Early data related to DAOCs show DOACs have an improved psychological impact compared with 
warfarin in elderly patients.32 Apixaban, DOAC, has stable and predictable clinical pharmacology and 
does not require laboratory monitoring. Apixaban also does not interfere with food and has fewer 
interactions with other drugs compared to warfarin.  Therefore it is foreseeable the physiological benefit 
this could provide, especially when compared to warfarin.  
 
Social, and legal 
We do not foresee any benefit in this regard. 
 
Long range potential benefits 
Physical  
As discussed above major long benefit will be a reduction in thromboembolism, whether that is warfarin 
or Apixaban.  
 
• 
Apixaban (ELIQUIS) 
Benefits discussed above in immediate risk.  
 
• 
Warfarin 
Benefits discussed above in immediate risk.  
 
Psychological 
Benefits discussed above in immediate risk.  
 
Social, and legal 
We do not foresee any benefit in this regard. 
 
2.3.3 ASSESSMENT OF POTENTIAL RISKS AND BENEFITS  
Include an assessment of known potential risks and benefits, addressing each of the following: 
• 
Rationale for the necessity of exposing participants to risks and a summary of the ways that risks 
to participants were minimized in the study design 
• 
Justification as to why the risks of participation in the study outweigh the value of the 
information to be gained 
 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
In our trial, patients will have a CHA2DS2-VASc score ≥2 and considered by the treating physician for 
anticoagulation to reduce the risk of stroke in the setting of NVAF as per American Heart Association 
guideline. In other words, patients with this score and NVAF in general practice would be offered 
anticoagulation. Therefore, although patients are being exposed to a drug which could cause some 
adverse and rarely fatal reactions – this exposure would not be out of the realm of ordinary evidenced 
based clinical practice. That said, risks in particular with bleeding will be minimized by ensuring 
monitoring of the patients (eg. INR for warfarin, creatinine for Apixaban) and education regarding these 
risks. 
Education will be provided to patients regarding signs of obvious bleeding, management of diet, and 
how to manage medications during travel using educational brochures. 
 
 
3 
OBJECTIVES AND ENDPOINTS 
 
OBJECTIVES 
ENDPOINTS 
JUSTIFICATION FOR ENDPOINTS 
Primary 
 
 
To assess the change in 
global cognitive function 
using standardized 
neurocognitive assessment in 
patients with atrial 
fibrillation over the age of 60 
years with CHA2DS2-VASc 
score ≥2 treated with 
Apixaban versus warfarin 
 
The individual cognitive domain and 
global cognitive function score using 
a battery of standardized 
neurocognitive function tests 
(presented below in detail). 
o All enrolled subjects will 
undergo assessment of 
cognitive function at (1) 
before or within 1 month of 
randomization (2) 1 year and 
(3) 2 years.  
 
 
 
Cognitive function scores are 
chosen as the primary end point 
due to their sensitivity to detect 
changes in cognitive function 
within a short span of time. 
While dementia is also an 
important end point, it is 
increasingly recognized that 
milder degrees of cognitive 
dysfunction are more prevalent 
and may have an important 
impact on a person’s quality of 
life and morbidity. Early 
recognition of cognitive decline 
can lead to earlier intervention 
to either treat or prevent 
progression. Hence the primary 
end point of decline in cognitive 
function in one or more domains 
will be a clinically relevant and a 
patient centered outcome.  
 
Additionally, AF may have a 
greater impact on non-memory 
cognitive domains such as 
executive function, thus 
predisposing to non-amnestic 
dementia. Hence we will test 
individual cognitive domains to 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
OBJECTIVES 
ENDPOINTS 
JUSTIFICATION FOR ENDPOINTS 
increase the sensitivity of the 
tests.  
 
 
Secondary 
 
 
To assess the development of 
mild cognitive impairment or 
dementia  
Clinical dementia rating scale 
 
Dementia 
Subjects with a CDR 1 will be 
classified as demented if they meet 
DSM-V 
criteria 
for 
‘major 
neurocognitive disorder’ as follows: 
1. Evidence 
of 
significant 
cognitive decline from a 
previous 
level 
of 
performance in one or more 
cognitive domains based on: 
a. Concern 
of 
the 
individual, 
a 
knowledgeable 
informant, or the 
clinician that there 
has 
been 
a 
significant decline in 
cognitive 
function; 
and 
b. A 
substantial 
impairment 
in 
cognitive 
performance, 
preferably 
documented 
by 
standardized 
neuropsychological 
testing. 
2. The 
cognitive 
deficits 
interfere with independence 
in everyday activities. 
3. The cognitive deficits do not 
occur 
exclusively 
in the 
context of delirium and are 
not better explained by 
another mental disorder. 
 
For subjects with CDR 0.5, a 
committee 
of 
the 
examining 
The development of dementia 
or mild cognitive impairment are 
important end points with 
clinical relevance to the patient. 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
OBJECTIVES 
ENDPOINTS 
JUSTIFICATION FOR ENDPOINTS 
neuropsychologist and physician will 
critically examine the available tests 
to determine whether the DSM-V 
criteria for dementia or MCI are met.  
 
Mild cognitive impairment 
The criteria for diagnosis of MCI are: 
cognitive concern expressed by a 
physician, informant, participant or 
nurse; cognitive impairment in 1 or 
more domains; normal functional 
activities 
and 
not 
demented. 
Subjects with MCI can have a CDR of 
0 or 0.5; however, the final diagnosis 
of MCI will not be based exclusively 
on the CDR but rather on all 
available data. A committee of the 
examining neuropsychologist and 
physician will critically examine the 
available tests to determine whether 
the criteria for MCI are met.   
 
 
Tertiary end points 
 
 
MRI detected new cerebral 
ischemic lesions and cerebral 
microbleeds (CMBs) 
Brain MRI will be performed at 
baseline and 2 years to assess the 
presence of new cerebral ischemic 
lesions on DTI imaging and new 
cerebral microbleeds on SWAN 
sequences. 
The presence of cerebral 
infarcts, even clinically silent 
ones, have been associated with 
higher future risk of dementia. 
Similarly, CMBs are associated 
with dementia and future risk 
for intracerebral hemorrhage. 
 
 
 
4 
STUDY DESIGN  
 
4.1 
OVERALL DESIGN AND SCIENTIFIC RATIONALE FOR STUDY DESIGN 
 
Our primary hypothesis is that in patients with atrial fibrillation, anticoagulation with Apixaban reduces 
the rate of decline in cognitive function, when compared to Warfarin. We also hypothesize that 
Apixaban reduces cognitive decline by reducing the rate of new cerebral infarction and cerebral 
microbleeds detected by cerebral MRI compared to warfarin.  
 
This is a phase 3, open-label, single site, randomized control trial comparing neuropsychological and 
neuroimaging outcomes in AF patients randomized to Apixaban vs Warfarin. Patients over the age of 60 
y with ECG documentation of NVAF in patient records and CHA2DS2VaSC score ≥2, eligible for oral 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
anticoagulation will be randomized to Apixaban or dose adjusted warfarin (target INR 2 – 3) for a period 
of 2 years. Randomization will be stratified by decade of age, and gender. All patients will undergo 
neuropsychometric testing at baseline, 1 and 2 years and brain MRI at baseline and 2 years. Study 
personnel performing and interpreting the neuropsychometric tests and brain MRI will be blinded to 
treatment allocation.  
 
Specific objectives 
Primary objective:  To assess the decline in cognitive function using standardized neurocognitive 
assessment in patients with atrial fibrillation over the age of 60 years with CHA2DS2-VASc score ≥2 
treated with Apixaban versus warfarin 
Our hypothesis is that Apixaban is associated with reduction in decline of cognitive function scores when 
compared to dose adjusted warfarin with goal INR of 2 – 3. We will test this hypothesis by randomizing 
patients with AF over the age of 60 years and CHA2DS2-VASc score ≥2 to anticoagulation with Apixaban 
vs Warfarin. The primary endpoint of this study is the longitudinal change in cognitive function scores 
over a follow-up of 2 years in individual cognitive domains (executive, language, memory and 
visuospatial) and global cognitive function. The development of mild cognitive impairment or dementia 
will also be assessed as a secondary end point. By the end of this study it is our expectation that the risk 
of cognitive impairment in AF patients taking Apixaban compared to Warfarin will be well defined and 
such results will provide a novel measure to reduce the burden of cognitive impairment in AF.   
Rationale: Cognitive function scores are chosen as the primary end point due to their sensitivity to 
detect changes in cognitive function within a short span of time. While dementia is also an important 
end point, it is increasingly recognized that milder degrees of cognitive dysfunction are more prevalent 
and may have an important impact on a person’s quality of life and morbidity. Early recognition of 
cognitive decline can lead to earlier intervention to either treat or prevent progression. Hence the 
primary end point of decline in cognitive function in one or more domains will be a clinically relevant 
and a patient centered outcome.  
Secondary objective: To determine the incidence of new cerebral infarct and new cerebral microbleeds 
using cerebral MRI in AF patients treated with Apixaban vs warfarin.  
The secondary objective is to evaluate the impact of Apixaban on subclinical emboli and CMBs detected 
by brain MRI compared to Warfarin. Our hypothesis is that Apixaban is associated with fewer new 
subclinical emboli and CMBs, compared to warfarin. This has important clinical implications as reduction 
in these has significant potential to reduce the risk of cognitive impairment.   
Rationale: There is growing evidence of the important relationship between subclinical emboli and 
cerebral microbleeds (CMBs) and the development of cognitive impairment. These MRI findings can be 
viewed as ‘bio-markers’ of risk of future cognitive decline. 
4.2 
JUSTIFICATION FOR DOSE 
Drug dosing will be in compliance with FDA approved recommendations. There will be NO off-label use 
of drugs. 
Apixaban 
5 mg twice daily unless patient has any 2 of the following: Age ≥80 years, body weight ≤60 kg, or serum creatinine 
≥1.5 mg/dL, then reduce dose to 2.5 mg twice daily. 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
Further dose adjustment will be performed in special circumstances as per FDA approved Apixaban drug 
label as follows: 
For patients qualifying for Apixaban 5 mg twice daily, the dose of Apixaban will be decreased by 50% 
when co-administered with drugs that are strong dual inhibitors of CYP3A4 and P-gp (e.g., ketoconazole, 
itraconazole, ritonavir, or clarithromycin).  
Warfarin 
Dose adjusted to maintain INR between 2 – 3. Dose adjustment performed using a standardized 
nomogram at an anti-coagulation clinic will be encouraged but not required. Interval of INR testing will 
be determined by the treating physician. 
 
4.3 
END OF STUDY DEFINITION 
A participant is considered to have completed the study if he or she has completed all phases of the 
study including the last visit or the last scheduled procedure shown in the Schedule of Activities (SoA), 
Section 1.3. 
 
The end of the study is defined as completion of the last visit or procedure shown in the SoA in the trial 
globally. 
 
5 
STUDY POPULATION 
 
5.1 
INCLUSION CRITERIA 
In order to be eligible to participate in this study, an individual must meet all of the following criteria: 
1. Patients diagnosed with atrial fibrillation based on electrocardiographic documentation 
2. Male or female greater than or equal to the age of 60 years, 
3. Have a CHA2DS2-VASc score ≥2 
4. Have never been treated with Apixaban, or prior treatment with Apixaban <1 month. 
 
5. Provision of signed and dated informed consent form 
6. Stated willingness to comply with all study procedures and availability for the duration of the 
study  
7. Ability to take oral medication and be willing to adhere to the study intervention regimen 
 
5.2 
EXCLUSION CRITERIA 
An individual who meets any of the following criteria will be excluded from participation in this study: 
 
1. Patients who are not a candidate for oral anticoagulation as assessed by a treating physician 
including the presence of active bleeding. 
2. Prior treatment with Apixaban for >1 month. (Prior exposure to warfarin or novel direct oral 
anticoagulants other than Apixaban is not an exclusion criterion). 
3. Known hypersensitivity to warfarin or Apixaban. 
4. CHA2DS2-VASc score <2 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
5. Valvular AF defined as history of rheumatic valve disease, moderate or greater mitral stenosis, 
and presence of a mechanical cardiac valve. 
6. Need for dual anti-platelet therapy with aspirin and another agent such as a thienopyridine.   
7. Aspirin monotherapy with doses > 100 mg if the patient is unable to reduce the dose to <100 
mg. 
8. Severe renal insufficiency (serum creatinine level of >2.5 mg/dl or calculated creatinine 
clearance of <25 ml/minute) or dialysis. 
9. Prior severe bleeding including intracranial hemorrhage and GI bleed requiring transfusion. 
10. Recent stroke (within 7 d) 
11. Known diagnosis of dementia or dementia diagnosed at first evaluation. 
12. Presence of MRI non-compatible implanted devices including cardiac implantable electronic 
devices. Patients with MRI conditioned cardiac implantable electronic devices will also be 
excluded. This is done in light of concerns regarding patient safety in MRI scanner. 
13. Inability to undergo MRI due to claustrophobia. 
14. Current or expected systemic treatment with strong dual inducers of CYP3A4 and P-gp (e.g., 
rifampin, carbamazepine, phenytoin, St. John’s wort) because such drugs will decrease exposure 
to apixaban 
15. Current or expected systemic treatment with strong dual inhibitors of CYP3A4 and P-
glycoprotein (e.g., e.g., ketoconazole, itraconazole, ritonavir, or clarithromycin) in patients who 
would qualify for Apixaban dose of 2.5 mg BID.  
16. Currently enrolled in another investigational device or drug trial that has not completed the 
primary endpoint or that clinically interferes with the current study endpoints. 
17. Co-morbid condition(s) that could limit the subject's ability to participate in the trial or to 
comply with follow-up requirements, or that could impact the scientific integrity of the trial. 
18. Prisoners or subjects who are involuntarily incarcerated. Subjects who are compulsorily 
detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness. 
19. Severe comorbid condition with life expectancy ≤1 y 
20. Active alcohol or drug abuse or psychosocial reasons that make study participation impractical. 
 
5.3 
LIFESTYLE CONSIDERATIONS 
 
 
Warfarin arm: 
• 
Consumption of consistent quantities of vitamin K containing food from day to day will assist in 
the maintenance of your INR in the therapeutic range. (Patients will be provided a copy of the 
Mayo Clinic booklet on dietary regulation in warfarin treated patients as a guide.) 
 
5.4 
SCREEN FAILURES 
Screen failures are defined as participants who consent to participate in the clinical trial but are not 
subsequently randomly assigned to the study intervention or entered in the study. An example of a 
screen failure is someone who is diagnosed with newly recognized dementia or intracerebral 
hemorrhage following the administration of the baseline neurocognitive assessment and brain MRI. 
Information on screen failures will be collected for purposes of reporting as follows: demography, 
eligibility criteria, reason for screen failure and any serious adverse event.  
 
Individuals who do not meet the criteria for participation in this trial (screen failure) will not be 
rescreened.  

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
 
5.5 
STRATEGIES FOR RECRUITMENT AND RETENTION 
 
1. This is a single center study that will be conducted at the Mayo Clinic, Rochester, MN. Target 
study sample is total of 280 patients. Assuming a screen failure rate of 20%, target accrual is 350 
participants. Accrual will be completed in 1 year. The last patient will complete follow-up 2 years 
later.   
2. In order to enrich the study for the population at risk of the primary end point, at least 50% of 
the enrollees will be >70 y of age.  
3. Participants will be identified using two strategies: (1) Individuals with AF living in the 8 counties 
of Southeast Minnesota (Dodge, Fillmore, Goodhue, Houston, Olmsted, Mower, Wabasha and 
Winona counties) will be screened for eligibility. Such patients will be identified using the record 
linkage system of the Rochester Epidemiology Project and Mayo Clinic, Rochester clinical 
records. Potential participants with AF diagnosed in Olmsted county have already been 
identified through prior work the investigators have done. (2) Individuals seen in the inpatient 
and outpatient clinics at Mayo Clinic, Rochester, MN with a diagnosis of AF will also be screened 
for eligibility. Such patients will be identified by the treating physician, using screening of their 
medical records and through the Mayo ECG laboratory which flags patients with new 
identification of AF.  
4. Potential participants will be approached using one or more of the following: (1) direct patient 
contact in the clinic or hospital, (2) through letters and (3) phone calls. 
5. The ECG documentation of AF will be confirmed using review of the medical records. Eligibility 
for the study will be determined first using medical records and confirmed by direct interview of 
the patient prior to enrollment.  
6. Participants will be compensated for their participation in the study as follows: (1) each 
participant will be given $15 at the time of each neurocognitive assessment and (2) a Mayo 
parking voucher at the time of each MRI assessment. The compensation is intended to 
encourage patients to continue study related tests by providing partial compensation for travel 
expenses.  
 
6 
STUDY INTERVENTION 
 
6.1 
STUDY INTERVENTION(S) ADMINISTRATION 
 
6.1.1 STUDY INTERVENTION DESCRIPTION 
Study intervention  
Participants will be randomly assigned 1:1 to one of 2 treatment arms. Randomization will be stratif 
ied by decade of age and gender. Drug administration will be according to the FDA approved labeling. 
Treatment arm 1 (Apixaban arm) will receive Apixaban 5 mg twice daily unless patient has any 2 of the 
following: Age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, then reduce dose to 2.5 
mg twice daily. 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
For patients receiving a non-Apixaban anticoagulant at the time of enrollment, the following procedure 
will be followed to convert them to Apixaban: 
Conversion from warfarin to apixaban: Discontinue warfarin and initiate apixaban when INR is <2 
Conversion from other non-warfarin anticoagulants (oral or parenteral) to apixaban: Discontinue the 
other non-warfarin anticoagulant and begin taking apixaban at the usual time of the next scheduled 
dose of the other non-warfarin anticoagulant. 
Treatment arm 2 (Warfarin arm) will receive dose adjusted warfarin to maintain INR between 2 – 3. 
Dose adjustment performed using a standardized nomogram at an anti-coagulation clinic will be 
encouraged but not required. Interval of INR testing will be determined by the treating physician. 
For patients receiving a non-Apixaban oral anticoagulant at the time of enrollment, the following 
procedure will be followed to convert them to Warfarin: The anticoagulant will be continued until the 
INR is ≥2.  
For patients receiving a parenteral anticoagulant at the time of enrollment to the warfarin arm, the 
treating physician will determine the need for ‘bridging’ anticoagulation until the INR is therapeutic.  
6.1.2 DOSING AND ADMINISTRATION 
Apixaban 
5 mg twice daily unless patient has any 2 of the following: Age ≥80 years, body weight ≤60 kg, or serum 
creatinine ≥1.5 mg/dL, then reduce dose to 2.5 mg twice daily. Oral administration. 
For patients qualifying for Apixaban 5 mg twice daily, the dose of Apixaban will be decreased by 50% 
when co-administered with drugs that are strong dual inhibitors of CYP3A4 and P-gp (e.g., ketoconazole, 
itraconazole, ritonavir, or clarithromycin).  
Need for dose adjustment will be performed at the 1 year mark or sooner if the patient’s age, weight or 
creatinine warrant this.  
Warfarin 
Dose adjusted to maintain INR between 2 – 3. Dose adjustment performed using a standardized 
nomogram at an anti-coagulation clinic will be encouraged but not required. Interval of INR testing will 
be determined by the treating physician. Oral administration. 
6.2 
PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY 
 
Apixaban arm: The drug will be provided by and paid for by BMS / Pfizer. The drug will be provided to 
Mayo Clinic. It will be distributed to patients once every 6 months via mail by the Mayo Clinic Pharmacy. 
Apixaban will be stored at 20°C to 25°C (68°F-77°F); excursions permitted between 15°C and 30°C 
(59°F-86°F) per the drug labeling. 
 
Warfarin arm: Warfarin will be prescribed by the treating physician. INR monitoring and dose 
adjustment will also be performed by the treating physician / assigned anticoagulation clinic. Warfarin 
will not be provided or paid for by the study. 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
 
6.3 
MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING 
 
Study participants will be randomized 1:1 to either Apixaban or dose adjusted Warfarin. Placebo pills will 
not be administered. Participants, the principal investigator and study coordinator will not be blinded to 
treatment assignment. Study personnel administering and interpreting the MRI images and cognitive 
function assessment will be blinded to treatment assignment. Randomization codes will be generated at 
the time of enrollment and each individual’s cognitive function tests and MRI scan identified by this 
code. Blinding of participants in this study will require the use of placebo and INR testing in both groups, 
which will be burdensome to the patient and will not affect the outcomes of cognitive function or MRI 
findings.  
 
Unblinding of personnel to treatment assignment will be performed only when there is a serious 
adverse event such as intra-cranial hemorrhage.  
 
6.4 
CONCOMITANT THERAPY 
For this protocol, a prescription medication is defined as a medication that can be prescribed only by a 
properly authorized/licensed clinician. Medications to be reported in the Case Report Form (CRF) are 
concomitant prescription medications, over-the-counter medications and supplements. Medication 
information will be collected at each neurocognitive assessment visit. A list of medications will be 
extracted from the most recent available medical records and confirmed in person with the patient. This 
will be performed by the study coordinator. 
 
 
6.4.1 RESCUE MEDICINE 
The study site will not supply rescue medication that will be obtained locally.  
The following rescue medications / treatments may be used in the setting of hemorrhagic adverse 
events at the discretion of the treating physician. 
 
 
Apixaban: Discontinue therapy with active pathological hemorrhage and promptly evaluate for 
bleeding source.  
A specific antidote for Apixaban is not available, and there is no established way to reverse 
bleeding in patients taking Apixaban. The pharmacodynamic effect of Apixaban can be 
expected to persist for at least 24 hours after the last dose, i.e., for about two drug half-lives. 
Use of procoagulant reversal agents, such as prothrombin complex concentrate (PCC), 
activated prothrombin complex concentrate or recombinant factor VIIa, may be considered but 
has not been evaluated in clinical studies. When PCCs are used, monitoring for the 
anticoagulation effect of apixaban using a clotting test (PT, INR, or aPTT) or anti-factor Xa 
(FXa) activity is not useful and is not recommended. A preclinical study evaluated the impact of 
different clotting factors in reversing actions of apixaban. A high concentration of apixaban (200 
ng/mL) was added to blood from healthy donors in vitro and blood-clotting response was 
evaluated when prothrombin complex concentrates (PCCs; product not specified), activated 
prothrombin complex concentrates (aPCCs), and recombinant factor VII (rFVIIa) were added. 
PCC and aPCC seemed to be more efficient in restoring generation of thrombin, while rFVIIa 
was the quickest to produce a compact blood clot and most effective in studies with blood 
circulating through a damaged blood vessel. Activated oral charcoal reduces absorption of 
apixaban, thereby lowering apixaban plasma concentration. The use of activated oral charcoal 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
may be considered if ingestion occurred within 2 to 6 hours of presentation. Hemodialysis does 
not appear to have a substantial impact on apixaban exposure. Protamine sulfate and vitamin K 
are not expected to affect the anticoagulant activity of apixaban. There is no experience with 
antifibrinolytic agents (tranexamic acid, aminocaproic acid) in individuals receiving apixaban. 
There is no experience with systemic hemostatics (desmopressin and aprotinin) in individuals 
receiving apixaban, and they are not expected to be effective as a reversal agent. 
 
Warfarin: If bleeding occurs, check INR and discontinue use. Depending on the severity of the 
bleeding intravenous fresh frozen plasma and oral or intravenous Vitamin K can be used to 
reverse the anticoagulant effect of warfarin. 
 
7 
STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL 
 
7.1 
DISCONTINUATION OF STUDY INTERVENTION 
Discontinuation from study intervention (anticoagulant use) does not mean discontinuation from the 
study, and remaining study procedures should be completed as indicated by the study protocol.  If a 
clinically significant finding is identified (including, but not limited to changes from baseline) after 
enrollment, the investigator or qualified designee will determine if any change in participant 
management is needed. Any new clinically relevant finding will be reported as an adverse event (AE). 
Events that may trigger include: 
1. Major bleeding event. The anticoagulant will be discontinued and future management of 
anticoagulant will be decided by the treating physician. The patient will not be re-challenged 
with anticoagulant as part of the study protocol. 
2. Ischemic Stroke / TIA. Management of anticoagulant in the first month following an ischemic 
stroke / TIA will be determined by the treating physician. Following this, a decision regarding 
whether to continue study intervention will be made in consultation with the treating physician 
and the patient. Whether the anticoagulant was being used in a therapeutic fashion at the time 
of event will be part of this discussion. 
3. Hemorrhagic stroke. The study intervention will be discontinued and future anticoagulation 
decision will be made by the treating physician. 
4. Participants will be strongly encouraged by the study staff to remain on treatment assigned 
through randomization and to comply with the study protocol and follow-up. However, 
participants or their physician may voluntarily discontinue study intervention or change OAC 
treatment at any time. Study staff will make every effort to discourage this. 
 
Participants who change OAC treatment during follow-up will be withdrawn from the study. A CRF will 
collect details of the reason for discontinuation of study intervention. Endpoints will be assessed at the 
time of withdrawal from the study including MRI and cognitive function. The MRI of the head and / or 
cognitive assessment will be performed at the time of withdrawal from the study if it is greater than 6 
months since their last assessment of MRI and / or cognitive function.  If a patient withdraws within 6 
months of the last assessment, repeat testing will not be performed and the last assessment will be 
used for the analysis.  Participants who withdraw from the study will be followed for 30 days after 
withdrawal for adverse events. A primary intention to treat analysis will be performed at the end of the 
study. Participants who withdraw or change OAC treatment will be censored at the time of withdrawal.  
 
7.2 
PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
Participants are free to withdraw from participation in the study at any time upon request. 
An investigator may discontinue or withdraw a participant from the study for the following reasons: 
 
• 
Significant study intervention non-compliance  
• 
If any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation 
occurs such that continued participation in the study would not be in the best interest of the 
participant 
• 
If the participant meets an exclusion criterion (either newly developed or not previously 
recognized) that precludes further study participation. 
The reason for participant discontinuation or withdrawal from the study will be recorded on the Case 
Report Form (CRF). Subjects who sign the informed consent form and are randomized but do not receive 
the study intervention may be replaced.   
 
7.3 
LOST TO FOLLOW-UP 
A participant will be considered lost to follow-up if he or she fails to return for a visit within a 6 month 
time frame and is unable to be contacted by the study site staff.  
 
The following actions will be taken if a participant fails to return to the clinic for a required study visit: 
• 
The study coordinator will attempt to contact the participant and reschedule the missed visit 
within 2 weeks and counsel the participant on the importance of maintaining the assigned visit 
schedule and ascertain if the participant wishes to and/or should continue in the study. 
• 
Before a participant is deemed lost to follow-up, the investigator or designee will make every 
effort to regain contact with the participant (3 telephone calls and, if necessary, a certified letter 
to the participant’s last known mailing address). These contact attempts will be documented in 
the participant’s medical record or study file.  
• 
Should the participant continue to be unreachable, he or she will be considered to have 
withdrawn from the study with a primary reason of lost to follow-up. 
• 
If a participant is reachable but is unable to come in person for the study visit, a telephone 
interview will be conducted with the participant and an informant to assess the secondary end 
point of dementia / MCI.  
8 
STUDY ASSESSMENTS AND PROCEDURES 
 
8.1 
EFFICACY ASSESSMENTS  
Screening assessment 
Screening for eligible participants will be performed using the Mayo medical records by a study 
coordinator. Only patients who have previously given consent to the use of their medical records for 
research purposes will be screened. ECG, Holter, telemetry recordings will be reviewed to confirm the 
diagnogsis of AF. Charts will be reviewed to assess eligibility for the study including past medical history, 
current medications, laboratory tests and calculation of the CHA2DS2-VaSC score. The creatinine will be 
checked if a measurement within 3 months of enrollment is not available.  
 
Potential participants will be contacted in person or through a letter or on the phone. Interested 
persons will be interviewed on the phone to confirm eligibility and will have a blood test for creatinine if 
needed. Once enrolled, subjects will be randomized to one of the study arms and will start study drug. 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
Baseline assessment of brain MRI will be performed prior to initiation of study drug. Baseline 
assessment of cognitive function will be performed prior to or within 1 month of enrollment. 
Subsequent assessments will be performed at 1 and 2 year follow-up or within a 3 month time frame of 
this date. 
Measurement of primary endpoint: The individual cognitive domain and global cognitive function 
score 
All enrolled subjects will undergo assessment of cognitive function at (1) enrollment, (2) 1 year and (3) 2 
years. 
AF may have a greater impact on non-memory cognitive domains such as executive function, thus 
predisposing to non-amnestic dementia. Hence we will test individual cognitive domains to increase the 
sensitivity of the tests.  
The following standardized tests will be administered at each visit by a trained neuropsychometrist.  
Testing of four major cognitive function domains 
1. Executive function - Trail Making Test B and Digit Symbol Substitution Test 
2. Language - Boston Naming Test and Category Fluency  
3. Memory - Logical Memory-II (delayed recall), Visual Reproduction-II (delayed recall) and 
Auditory Verbal Learning Test (delayed recall)  
4. Visuospatial - Picture Completion and Block Design 
Questionnaires to rule out competing diagnoses: 
1. 
The Beck Depression Inventory  
2. 
The Beck Anxiety Inventory  
An informant, identified by the subject as someone with whom they have contact at least once every 
week, will be interviewed in person or by telephone to complete the following: 
1. 
Clinical dementia rating scale (CDR) 
2. 
Functional assessment questionnaire 
For patients lost to clinic follow-up, assessment of cognitive state will be performed using the following 
questionnaires administered over the telephone: 
Telephone interview of cognitive status (TICS-M) (administered to subject) 
2. 
Clinical dementia rating scale (administered to informant) 
3. 
Functional assessment questionnaire (administered to informant) 
Adjustment of Neurocognitive function scores using normative data and derivation of ‘Global cognitive 
function score’ 
The raw scores on each neuropsychological test will be transformed into age- and education-adjusted 
scores using Mayo’s Older American Normative Studies normative data. The adjusted scores within each 
of the 4 domains will be added to obtain the domain specific score. Since different numbers of tests are 
used within each domain (i.e., 2 tests for the executive, language, and visuospatial domains versus 3 
tests for memory), the domain scores will also scaled for the number of tests to allow comparisons 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
across domains. The global cognitive function score will then be derived using an average of the 4 
domain specific scores.  
The performance of a person in a particular domain and their global performance will then be measured 
by comparing the person’s score with the score in normal person that has been previously established to 
derive a ‘z-score’. These comparisons rely on extensive previous normative work we have performed in 
assessing the cognitive abilities of the population from which the sample will be derived.33, 34 The tests 
and definitions provided here have been previously described in detail by our group.34 The tests will 
parallel those used by the NIH funded Mayo Clinic Study of Aging, a large ongoing community based 
study of cognitive function in Olmsted County, MN. 
The ‘z-score’ in individual cognitive domains and the global cognitive function score will be plotted at 
each time point for the two treatment groups to assess temporal changes. 
Measurement of secondary endpoint: Mild cognitive impairment or dementia 
The CDR score (range 0–3) will be assessed in addition to the results of the neuropsychological testing. A 
team of Neurologist and Neuropsychometrist will assign a diagnosis of normal cognition or mild 
cognitive impairment or dementia to each subject at each time point. This team will be blinded to 
treatment assignments. Each assessment of an individual patient will be assessed independent of prior 
assessments. The definitions used are as follows: 
Dementia 
Subjects with a CDR 1 will be classified as demented if they meet DSM-V criteria for ‘major 
neurocognitive disorder’ as follows: 
1. Evidence of significant cognitive decline from a previous level of performance in one or more 
cognitive domains based on: 
a. Concern of the individual, a knowledgeable informant, or the clinician that there has 
been a significant decline in cognitive function; and 
b. A substantial impairment in cognitive performance, preferably documented by 
standardized neuropsychological testing. 
2. The cognitive deficits interfere with independence in everyday activities. 
3. The cognitive deficits do not occur exclusively in the context of delirium and are not better 
explained by another mental disorder. 
For subjects with CDR 0.5, a committee of the examining neuropsychologist and physician will critically 
examine the available tests to determine whether the DSM-V criteria for dementia or MCI are met.  
Mild cognitive impairment 
The criteria for diagnosis of MCI are: cognitive concern expressed by a physician, informant, participant 
or nurse; cognitive impairment in 1 or more domains; normal functional activities and not demented. 
Subjects with MCI can have a CDR of 0 or 0.5; however, the final diagnosis of MCI will not be based 
exclusively on the CDR but rather on all available data. A committee of the examining neuropsychologist 
and physician will critically examine the available tests to determine whether the criteria for MCI are 
met.   
Normal Cognition 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
Subjects judged to have no cognitive impairment based on the criteria above and received a CDR of 0, 
will be considered as cognitively normal.  
Brain MRI imaging to assess burden of cerebral infarcts and cerebral microbleeds 
MR Imaging of brain 
Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner at enrollment and 
at 2 years. If a subject is withdrawn or withdraws prior to the completion of follow-up, an attempt to 
obtain MRI prior to withdrawal will be made. The following imaging sequences will be performed per 
standard protocols at our institution: (1) sagittal T1-weighted, (2) axial T2-weighted fast spin echo (FSE), 
(3) axial T2-weighted fluid-attenuated inversion recovery (FLAIR), (4) axial gradient echo (GRE), (5) axial 
diffusion tensor-tracer imaging (DTI),  (7) 3-dimensional magnetization prepared rapid gradient-echo 
(MPRAGE) sequence and (8) Axial SWAN (T2 Star Weighted Angiography). 
The MRI will be read by a board certified Radiologist who is blinded to treatment assignment.  
A new cerebral infarct will be defined as an unequivocal focus of hyperintensity to gray matter on DTI 
images. GRE and MPRAGE sequences will be used to quantitate the cerebral microbleeds. Cerebral 
volume analysis will be performed for total cerebral and hippocampal volume using standardized 
software. The number, size and location of new cerebral infarcts (cortical vs. subcortical and specific 
anatomic location of infarct) and cerebral microbleeds (lobar vs subhemispheric and specific anatomic 
location of infarct) will be determined and documented in a CRF.   
Interview by study coordinator 
Interview of the subject by study coordinator at 1- and 2- year follow-up to assess (1) new medical 
conditions, (2) adverse events, (3) continued eligibility for the study, (4) medication compliance and (5) 
review of co-administered medications. 
Other assessments 
Patients will undergo the following tests at enrollment:  
(1) serum creatinine to determine eligibility for the study and Apixaban dosing  
 
8.2 
SAFETY AND OTHER ASSESSMENTS 
1. Assessment for adverse events will be performed on an ongoing basis and at each patient visit.  
2. At each study visit, the participant will be interviewed by the study coordinator to assess for 
adverse events. The medical records will be reviewed on an ongoing basis to identify occurrence 
of adverse events and hospitalizations.  
3. Occurrence of medical events and addition of drugs that may affect continued eligibility for the 
study will be assessed at each visit. The age, creatinine and patient weight will be assessed at 
each patient visit to assess appropriateness of drug dosing.  
4. The brain MRI will be screened for adverse events such as identification of asymptomatic 
intracranial bleeding after each assessment.  
 
Definitions for a selection of important adverse events: 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
Major bleeding 
Major bleeding is defined as acute or subacute clinically overt bleeding with one or more of the 
following criteria: (1) Fatal bleeding and/or symptomatic bleeding in a critical area or organ, such as 
intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with 
compartment syndrome (2) Bleeding causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more 
over a 24 hr period, or (3) leading to transfusion of two or more units of whole blood or packed red cells. 
 
Clinically Relevant nonmajor Bleed 
A clinically relevant minor bleed is an acute or subacute clinically overt bleed that does not meet the 
criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following:  
• 
A hospital admission for bleeding, or 
• 
A physician guided medical or surgical treatment for bleeding, or 
• 
A change in antithrombotic therapy (including interruption or discontinuation of study drug). 
 
Minor Bleeding 
All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically 
relevant nonmajor bleeding will be classified as minor bleeding.  
   
8.3 
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS 
 
8.3.1 DEFINITION OF ADVERSE EVENTS (AE) 
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting 
medical condition in a clinical investigation participant administered study drug and that does not 
necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and 
unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of investigational product, whether or not considered related to the investigational 
product. 
The causal relationship to study drug is determined by a physician and should be used to assess all 
adverse events (AE). The casual relationship can be one of the following: 
Related: There is a reasonable causal relationship between study drug administration and the AE. 
Not related: There is not a reasonable causal relationship between study drug administration and the 
AE.  
The term "reasonable causal relationship" means there is evidence to suggest a causal relationship.  
Adverse events can be spontaneously reported or elicited during open-ended questioning, examination, 
or evaluation of a subject. (In order to prevent reporting bias, subjects should not be questioned 
regarding the specific occurrence of one or more AEs.) 
 
 
8.3.2 DEFINITION OF SERIOUS ADVERSE EVENTS (SAE)  
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:  

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
• 
results in death 
• 
is life-threatening (defined as an event in which the participant was at risk of death at the time of 
the event; it does not refer to an event which hypothetically might have caused death if it were 
more severe) 
• 
requires inpatient hospitalization or causes prolongation of existing hospitalization (see NOTE 
below) 
• 
results in persistent or significant disability/incapacity 
• 
is a congenital anomaly/birth defect  
• 
is an important medical event (defined as a medical event(s) that may not be immediately life-
threatening or result in death or hospitalization but, based upon appropriate medical and scientific 
judgment, may jeopardize the subject or may require intervention [eg, medical, surgical] to prevent 
one of the other serious outcomes listed in the definition above.) Examples of such events include, 
but are not limited to, intensive treatment in an emergency room or at home for allergic 
bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization.)  
• 
Suspected transmission of an infectious agent (eg, pathogenic or nonpathogenic) via the study drug 
is an SAE.  
Although pregnancy, overdose, adverse events of special interest, and cancer are not always serious by 
regulatory definition, these events must be handled as SAEs. 
Any component of a study endpoint that is considered related to study therapy should be reported as an 
SAE (eg, death is an endpoint, if death occurred due to anaphylaxis, anaphylaxis must be reported). 
The following hospitalizations are not considered SAEs in BMS clinical studies:  
− 
a visit to the emergency room or other hospital department < 24 hours, that does not result in 
admission (unless considered an important medical or life-threatening event) 
− 
elective surgery, planned prior to signing consent 
− 
admissions as per protocol for a planned medical/surgical procedure 
− 
routine health assessment requiring admission for baseline/trending of health status (eg, routine 
colonoscopy) 
− 
Medical/surgical admission other than to remedy ill health and planned prior to entry into the 
study. Appropriate documentation is required in these cases. 
− 
Admission encountered for another life circumstance that carries no bearing on health status and 
requires no medical/surgical intervention (eg, lack of housing, economic inadequacy, caregiver 
respite, family circumstances, administrative reason). 
 
8.3.2.1 EVENTS OF SPECIAL INTEREST  
In this study, the following adverse events are to be reported to BMS as serious events, regardless of 
whether these reports are classified as serious or unexpected: 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
Potential or suspected cases of liver injury including but not limited to liver test abnormalities, jaundice, 
hepatitis or cholestasis. 
 
8.3.2.2 PREGNANCY  
If, following initiation of the investigational product, it is subsequently discovered that a study 
participant is pregnant or may have been pregnant at the time of investigational product exposure, 
including during at least 5 half-lives after product administration, the investigational product will be 
permanently discontinued in an appropriate manner (eg, dose tapering if necessary for participant).  
The investigator must immediately notify Worldwide.Safety@bms.com of this event via either the 
CIOMS, MedWatch or appropriate Pregnancy Surveillance Form in accordance with SAE reporting 
procedures.  
Protocol-required procedures for study discontinuation and follow-up must be performed on the 
participant. 
Follow-up information regarding the course of the pregnancy, including perinatal and neonatal outcome 
and, where applicable, offspring information must be reported on the CIOMS, MedWatch or appropriate 
Pregnancy Surveillance Form.   
Any pregnancy that occurs in a female partner of a male study participant should be reported to BMS. 
Information on this pregnancy will be collected on the Pregnancy Surveillance Form. In order for 
Sponsor or designee to collect any pregnancy surveillance information from the female partner, the 
female partner must sign an informed consent form for disclosure of this information.  
 
8.3.2.3 OVERDOSE 
An overdose is defined as the accidental or intentional administration of any dose of a product that is 
considered both excessive and medically important. All occurrences of overdose must be reported as an 
SAE. 
 
 
8.3.3 CLASSIFICATION OF AN ADVERSE EVENT 
8.3.3.1 SEVERITY OF EVENT 
The intensity of the adverse event will be determined by a physician on the data monitoring and safety 
board as: 
• 
Mild (Grade 1): Event detected, but without any interference with activity 
• 
Moderate (Grade 2): Some interference with activities of daily living 
• 
Severe (Grade 3): Severe interference with activities of daily living 
• 
Very Severe (Grade 4): Resulting in severe disability despite medical therapy 
All SAEs will be grade 3 or 4 at minimum.  

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
8.3.3.2 RELATIONSHIP TO STUDY INTERVENTION 
The data monitoring and safety board physician will also classify the relationship of the AE to the study 
drug as follows: 
• 
Certain: There is sufficient medical data supporting causality of the AE to the study drug. The AE 
resolves or improves with withdrawal of the study drug and, when possible, recurs with 
reintroduction of study drug 
• 
Probable: There is sufficient medical data supporting causality of the AE to the study drug. The 
AE resolves or improves with withdrawal of the study drug. Reintroduction of the study drug is 
not required 
• 
Possible: There is sufficient medical data supporting causality of the AE to the study drug. The 
resolution or improvement of the AE with study drug withdrawal is unclear or did not occur.  
• 
Unlikely: There is insufficient medical data supporting the causality of the AE to the study drug, 
but a temporal relationship to study drug exposure is present.  
• 
       No relationship: There is no temporal relationship between study drug exposure and the AE. 
8.3.4 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW-UP 
 
The occurrence of an adverse event (AE) or serious adverse event (SAE) may come to the attention of 
study personnel during study visits and interviews of a study participant presenting for medical care, or 
upon review by a study monitor. 
 
All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured on the 
appropriate case report form (CRF). Information to be collected includes event description, time of 
onset, clinician’s assessment of severity, relationship to study product (assessed only by those with the 
training and authority to make a diagnosis), and time of resolution/stabilization of the event. All AEs 
occurring while on study will be documented appropriately regardless of relationship. All AEs will be 
followed to adequate resolution. 
 
Any medical condition that is present at the time that the participant is screened will be considered as 
baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any 
time during the study, it will be recorded as an AE.  
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event 
at each level of severity to be performed. AEs characterized as intermittent require documentation of 
onset and duration of each episode. 
 
Study coordinator will record all reportable events with start dates occurring any time after informed 
consent is obtained until 7 (for non-serious AEs) or 30 days (for SAEs) after the last day of study 
participation.  At each study visit, the investigator will inquire about the occurrence of AE/SAEs since the 
last visit.  Events will be followed for outcome information until resolution or stabilization. 
 
8.3.5 NON-SERIOUS ADVERSE EVENT REPORTING  

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
The collection of non-serious AE information should begin at initiation of study drug. All non-serious 
adverse events (not only those deemed to be treatment-related) should be collected continuously 
during the treatment period and for a minimum of 30 days following the last dose of study treatment.  
Non-serious AEs should be followed to resolution or stabilization, or reported as SAEs if they become 
serious. Follow-up is also required for non-serious AEs that cause interruption or discontinuation of 
study drug and for those present at the end of study treatment as appropriate.  
 
Nonserious Adverse events will be reported to the Data Safety and Monitoring Board every 3 months. 
 
Nonserious Adverse Events are provided to BMS via annual safety reports (if applicable), and interim or 
final study reports. 
 
 
8.3.6 SERIOUS ADVERSE EVENT REPORTING  
 
Following the subject’s written consent to participate in the study, all SAEs, whether or not related to 
the BMS product under study, must be collected, including those thought to be associated with 
protocol-specified procedures. SAEs must be recorded on FDA MedWatch 3500A Form and reported to 
BMS (or designee) within 24 hours/1 business day to comply with regulatory requirements. A form 
should be completed for any event where doubt exists regarding its status of seriousness.  Although 
overdose and cancer are not always serious by regulatory definition, these events should be recorded 
on a form and reported to BMS within 24 hours/1 business day. 
 
All SAEs must be reported by confirmed facsimile (fax) transmission or reported via electronic mail to: 
SAE Email Address: Worldwide.Safety@BMS.com  
SAE Facsimile Number:  1-609-818-3804  
 
If only limited information is initially available, follow-up reports may be required.  
 
For studies capturing SAEs through electronic data capture (EDC), electronic submission is the required 
method for reporting.  The paper forms should be used and submitted immediately, only in the event 
the electronic system is unavailable for transmission.  When paper forms are used, the original paper 
forms are to remain on site. 
 
If it is discovered a patient is pregnant or may have been pregnant at the time of exposure to the BMS 
product under study, the pregnancy, AEs associated with maternal exposure and pregnancy outcomes 
must be recorded on a Pregnancy Surveillance Form and reported to BMS (or designee) within 24 
hours/1 business day by confirmed fax or reported via electronic mail to Worldwide.Safety@BMS.com. 
If only limited information is initially available, follow-up reports may be required. The original BMS 
forms are to remain on site.  Follow-up information should be obtained on pregnancy outcomes for one 
year following the birth of the offspring.  
 
Any pregnancy that occurs in a female partner of a male study participant should be reported to BMS. 
Information on this pregnancy will be collected on the Pregnancy Surveillance Form. 
 
8.3.7 NONSERIOUS ADVERSE EVENT REPORTING  

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
The collection of non-serious AE information should begin at initiation of study drug. All nonserious 
adverse events (not only those deemed to be treatment-related) should be collected continuously 
during the treatment period and for a minimum of 30 days following the last dose of study treatment.  
Nonserious AEs should be followed to resolution or stabilization, or reported as SAEs if they become 
serious. Follow-up is also required for non-serious AEs that cause interruption or discontinuation of 
study drug and for those present at the end of study treatment as appropriate.  
Nonserious Adverse Events are provided to BMS via annual safety reports (if applicable), and interim or 
final study reports. 
8.3.8 SAE RECONCILIATION 
The investigator will reconcile the clinical database SAE cases transmitted to BMS Global 
Pharmacovigilance (GPV&E). Frequency of reconciliation will be done every three months and once prior 
to study database lock. BMS GPV&E will e-mail upon request from the investigator, the GPV&E 
reconciliation report. Requests for reconciliation should be sent to aepbusinessprocess@bms.com. The 
data elements listed on the GPV&E reconciliation report will be used for case identification purposes. If 
the investigator determines a case was not transmitted to BMS GPV&E, the case will be sent 
immediately. 
8.3.9 LABORATORY TEST ABNORMALITIES 
All laboratory test results captured as part of the study should be recorded following institutional 
procedures. Test results that constitute SAEs should be documented and reported to BMS as such. 
The following laboratory abnormalities should be documented and reported appropriately: 
• 
any laboratory test result that is clinically significant or meets the definition of an SAE 
• 
any laboratory abnormality that required the participant to have study drug discontinued or 
interrupted 
• 
any laboratory abnormality that required the subject to receive specific corrective therapy.  
It is expected that wherever possible, the clinical rather than laboratory term would be used by the 
reporting investigator (eg, anemia versus low hemoglobin value). 
 
8.3.10 OTHER SAFETY CONSIDERATIONS 
Any significant worsening noted during interim or final physical examinations, electrocardiograms, X-
rays, and any other potential safety assessments, whether or not these procedures are required by the 
protocol, should also be recorded as a non-serious or serious AE, as appropriate, and reported 
accordingly.  
 
8.3.11 REPORTING EVENTS TO PARTICIPANTS  
Study participants will be informed of any adverse events or incidental findings through a letter or 
phone call. In the case of a serious adverse event, the participant will be informed through a phone call 
within 48 hours of the occurrence. If patient is not reachable, attempts will be made to reach the 
alternative contact person and the primary treating physician, whose contact information will be sought 
from the subject at enrollment. The participant will be encouraged to seek care with the primary 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
treating physician to treat SAEs and to assess any incidental findings, such as findings on brain imaging 
that require further assessment.  
 
Interpretation of the brain MRI will be performed by a board certified clinical Radiologist and a report 
generated in the patient’s clinical record. This report will be shared with the participant through a letter. 
This report is however different from the more detailed analysis of the sequences that will be performed 
by the study Radiologist in a blinded fashion. The results of the cognitive function testing will be shared 
with individual participants only in the event of diagnosis of dementia, which is expected to have an 
impact on the overall management of the subject. The aggregate results of the study will be shared with 
all the participants once published in a peer review journal. 
 
 
8.4 
UNANTICIPATED PROBLEMS 
 
8.4.1 DEFINITION OF UNANTICIPATED PROBLEMS (UP) 
An UPIRTSO: An Unanticipated Problem Involving Risk to Subjects or Others is defined as any problem or 
event which, in the opinion of the Investigator, meets all three of the following criteria:  
1. Serious: Serious problems or events that result in significant harm, (which may be physical, 
psychological, financial, social, economic, or legal) or places subjects or others at a greater risk of harm 
than was previously known or recognized. Note that actual harm need not have occurred for there to be 
a change in the risk/benefit ratio.  
 
2. Unanticipated: A problem or event is "unanticipated" when it was unforeseeable at the time of its 
occurrence and is: 
 
Not already described as a potential risk in the approved informed consent 
Not already described as a potential risk in the approved protocol 
Not listed in the Investigator’s Brochure 
Not part of an underlying disease 
Occurred at an increased frequency or at an increased severity than expected  
 
3. Related: A problem or event is "related" if it is possibly related to the research procedures.  
 
8.4.2  UNANTICIPATED PROBLEM REPORTING  
The Investigator must report a UPIRTSO to the IRB, using the IRB electronic Reportable Event form, 
within five working days of becoming aware of the problem or event. The report will include a detailed 
description of the event, incident, experience, or outcome. 
 
All reportable events submitted to the IRB and meeting the UPIRTSO criteria will be sent to an IRB 
Chairperson for review. If the IRB Chairperson considers the event is a UPIRTSO, a convened IRB reviews 
it and determines whether it is a UPIRTSO or not. The investigator is notified in writing and the review, 
determination, and investigator communication is documented in the IRB electronic system.  
 
A UPIRTSO, as determined by the convened IRB, is reported to the Mayo Clinic Institutional Official and 
other relevant Federal agencies, when required, within 30 days from the date of IRB determination. The 
investigator is notified in writing of this action. 
 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
The investigator will submit a modification application to the IRB if the problem or event requires 
revision of the protocol and/or consent document. 
 
If the convened IRB confirms the UPIRTSO, the investigator reports the IRB's determination to the 
research project sponsor. 
 
 
8.4.3 REPORTING UNANTICIPATED PROBLEMS TO PARTICIPANTS  
Unanticipated problems occurring in individual subjects will be reported to the subject using the 
methods described for AEs and SAEs noted above.  
 
9 
STATISTICAL CONSIDERATIONS  
9.1 
STATISTICAL HYPOTHESES 
• 
Primary Efficacy Endpoint:  
 
Treatment with Apixaban is associated with reduced rate of decline in global cognitive function score 
compared to treatment with Warfarin in AF patients ≥ 60 years of age and CHA2DS2-VaSC score ≥2. 
 
Measurement of primary endpoint: The individual cognitive domain and global cognitive function 
score 
All enrolled subjects will undergo assessment of cognitive function at (1) enrollment, (2) 1 year and (3) 2 
years. 
AF may have a greater impact on non-memory cognitive domains such as executive function, thus 
predisposing to non-amnestic dementia. Hence we will test individual cognitive domains to increase the 
sensitivity of the tests.  
The following standardized tests will be administered at each visit by a trained neuropsychometrist.  
Testing of four major cognitive function domains 
5. Executive function - Trail Making Test B and Digit Symbol Substitution Test 
6. Language - Boston Naming Test and Category Fluency  
7. Memory - Logical Memory-II (delayed recall), Visual Reproduction-II (delayed recall) and 
Auditory Verbal Learning Test (delayed recall)  
8. Visuospatial - Picture Completion and Block Design 
Questionnaires to rule out competing diagnoses: 
1. 
The Beck Depression Inventory  
2. 
The Beck Anxiety Inventory  
An informant, identified by the subject as someone with whom they have contact at least once every 
week, will be interviewed in person or by telephone to complete the following: 
1. 
Clinical dementia rating scale (CDR) 
2. 
Functional assessment questionnaire 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
For patients lost to clinic follow-up, assessment of cognitive state will be performed using the following 
questionnaires administered over the telephone: 
Telephone interview of cognitive status (TICS-M) (administered to subject) 
2. 
Clinical dementia rating scale (administered to informant) 
3. 
Functional assessment questionnaire (administered to informant) 
 
Patients who no longer present for in person neurocognitive assessment will be censored from the 
analysis of the primary endpoint of neurocognitive function scores. The telephone interview will be used 
to classify as MCI / dementia and the data will be used for this secondary endpoint only.   
Adjustment of Neurocognitive function scores using normative data and derivation of ‘Global cognitive 
function score’ 
The raw scores on each neuropsychological test will be transformed into age- and education-adjusted 
scores using Mayo’s Older American Normative Studies normative data. The adjusted scores within each 
of the 4 domains will be added to obtain the domain specific score. Since different numbers of tests are 
used within each domain (i.e., 2 tests for the executive, language, and visuospatial domains versus 3 
tests for memory), the domain scores will also scaled for the number of tests to allow comparisons 
across domains. The global cognitive function score will then be derived using an average of the 4 
domain specific scores.  
The performance of a person in a particular domain and their global performance will then be measured 
by comparing the person’s score with the score in normal person that has been previously established to 
derive a ‘z-score’. These comparisons rely on extensive previous normative work we have performed in 
assessing the cognitive abilities of the population from which the sample will be derived.33, 34 The tests 
and definitions provided here have been previously described in detail by our group.34 The tests will 
parallel those used by the NIH funded Mayo Clinic Study of Aging, a large ongoing community based 
study of cognitive function in Olmsted County, MN. 
The ‘z-score’ in individual cognitive domains and the global cognitive function score will be plotted at 
each time point for the two treatment groups to assess temporal changes. 
 
• 
Secondary Efficacy Endpoints: 
 
Treatment with Apixaban is associated with lower rate of development of new dementia or mild 
cognitive impairment compared to treatment with warfarin. 
 
Measurement of secondary endpoint: Mild cognitive impairment or dementia 
The CDR score (range 0–3) will be assessed in addition to the results of the neuropsychological testing. A 
team of Neurologist and Neuropsychometrist will assign a diagnosis of normal cognition or mild 
cognitive impairment or dementia to each subject at each time point. This team will be blinded to 
treatment assignments. Each assessment of an individual patient will be assessed independent of prior 
assessments. The definitions used are as follows: 
Dementia 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
Subjects with a CDR 1 will be classified as demented if they meet DSM-V criteria for ‘major 
neurocognitive disorder’ as follows: 
1. Evidence of significant cognitive decline from a previous level of performance in one or more 
cognitive domains based on: 
a. Concern of the individual, a knowledgeable informant, or the clinician that there has 
been a significant decline in cognitive function; and 
b. A substantial impairment in cognitive performance, preferably documented by 
standardized neuropsychological testing. 
2. The cognitive deficits interfere with independence in everyday activities. 
3. The cognitive deficits do not occur exclusively in the context of delirium and are not better 
explained by another mental disorder. 
For subjects with CDR 0.5, a committee of the examining neuropsychologist and physician will critically 
examine the available tests to determine whether the DSM-V criteria for dementia or MCI are met.  
Mild cognitive impairment 
The criteria for diagnosis of MCI are: cognitive concern expressed by a physician, informant, participant 
or nurse; cognitive impairment in 1 or more domains; normal functional activities and not demented. 
Subjects with MCI can have a CDR of 0 or 0.5; however, the final diagnosis of MCI will not be based 
exclusively on the CDR but rather on all available data. A committee of the examining neuropsychologist 
and physician will critically examine the available tests to determine whether the criteria for MCI are 
met.   
Normal Cognition 
Subjects judged to have no cognitive impairment based on the criteria above and received a CDR of 0, 
will be considered as cognitively normal.  
 
Treatment with Apixaban is associated with lower incidence of new cerebral infarction and cerebral 
microbleeds noted on brain MRI imaging. 
 
Measurement of secondary endpoint:  This will be performed using brain MRI as noted above. 
 
9.2 
SAMPLE SIZE DETERMINATION 
Sample size calculation is based on the primary endpoint, the rate of decline in the global cognitive 
function score. The sample size calculations are based on data from the Mayo Clinic Study of Aging 
which has enrolled community dwelling individuals to perform the same battery of neurocognitive tests 
proposed in this study. We investigated the rate of decline in the global cognitive function score in (1) 
patients with and without AF and (2) in AF patients on warfarin vs. not on warfarin. The Mayo Clinic 
Study of Aging (MCSA) has identified a significant decline in the individual and global cognitive function 
scores in patients with AF compared to those without AF. In addition, the rate of decline was similar in 
AF patients treated with warfarin and those not treated with warfarin. The observed rate of decline in 
global cognitive score in AF patients on warfarin was -0.12 / year (SD 0.16). A reduction in the rate of 
decline in the global cognition function score of 0.05/year with Apixaban compared to Warfarin was 
considered clinically relevant. We used R to calculate power as a single sided test of superiority of 
Apixaban over Warfarin. A sample size of 140 in each arm is required to achieve >80% power to detect 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
the difference stated assuming an alpha error of 0.05. Assuming a screen failure rate of 20%, a total of 
175 will be accrued in each arm. 
 
Enrollment will be age and gender stratified with goal of enrolling >50% patients over the age of 70 
years in whom the risk of cognitive decline is greater. Recruitment of the required number of subjects 
will be feasible given the high volume of AF patients in the local community and those seeking care for 
AF at the Mayo Clinic. For example, 5000 individuals developed incident (new onset) AF in Olmsted 
county alone after the year 2000. The rate of prevalent AF is higher in this population. The other 7 
counties from which participants will be recruited have similar population demographics and prevalence 
of AF. We anticipate that we will be able to recruit the required number of subjects in the first year of 
the study. 
 
9.3 
POPULATIONS FOR ANALYSES 
The following datasets will be used for analysis: 
1. Intention-to-Treat (ITT) Analysis Dataset (i.e., all randomized participants) 
2. Per-Protocol Analysis Dataset: defines a subset of the participants in the full analysis set who 
complied with the protocol sufficiently to ensure that these data would be likely to represent 
the effects of study intervention according to the underlying scientific model. 
3. Pre-specified subgroup analyses – (1) Gender, (2) decade of age, (3) pattern of AF, (4) warfarin 
naïve vs prior warfarin exposure, (5) Time in therapeutic range on warfarin divided by the 
median. 
 
9.4 
STATISTICAL ANALYSES 
 
9.4.1 GENERAL APPROACH 
 
Continuous and categorical variables will be summarized as mean (standard deviation, SD) and number 
(%) respectively. Differences between the two treatment arms at baseline will be examined using t-tests 
for continuous variables and chi-square tests for categorical variables.   
 
The baseline variables include age, sex, education, cardiovascular risk factors (hypertension, diabetes 
mellitus, hyperlipidemia), past medical history (including stroke, TIA, heart failure, peripheral arterial 
disease, MI, coronary artery disease, liver disease, renal disease, malignancy), duration of AF, pattern of 
AF (paroxysmal, persistent), prior h/o anticoagulation (duration and type of drug used), prior treatment 
of AF (antiarrhythmic drug, ablation procedure), and current medications. This data will be reviewed and 
updated at each visit. The INR values during the study will be collected for patients on warfarin and the 
time in therapeutic range calculated using the Rosendaal method of interpolation. 
 
Longitudinal changes in each cognitive domain (language, attention, memory, visual spatial and global) 
will be analyzed using multiple adjusted linear mixed effects models comparing Apixaban vs warfarin.  
These models will be adjusted for baseline variables that differ between the groups. These results will be 
presented as beta estimates for baseline differences in cognitive function score by treatment status, 
change with time and the effect of treatment on the change in scores over time.  
 
For the secondary end point of dementia/MCI, the mid-point between the most recent visit with a 
cognitively normal diagnosis and the first visit with a diagnosis of MCI or dementia will be considered 
the date of onset. Participants who are lost to follow-up or die during follow-up will be censored at the 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
date of last follow-up. Cox proportional hazards model will be used to assess the secondary end points 
of MCI/dementia, cerebral infarction and cerebral microbleeds. Adjustment for baseline factors noted 
above will be performed in the multivariable model.  
 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS 
10.1 REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS 
10.1.1 INFORMED CONSENT PROCESS 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the 
study and continues throughout the individual’s study participation. Consent forms will be Institutional 
Review Board (IRB)-approved and the participant will be asked to read and review the document. The 
study coordinator / investigator will explain the research study to the participant and answer any 
questions that may arise. A verbal explanation will be provided in terms suited to the participant’s 
comprehension of the purposes, procedures, and potential risks of the study and of their rights as 
research participants.  Participants will have the opportunity to carefully review the written consent 
form and ask questions prior to signing. The participants should have the opportunity to discuss the 
study with their family or surrogates or think about it prior to agreeing to participate. The participant 
will sign the informed consent document prior to any procedures being done specifically for the study. 
Participants must be informed that participation is voluntary and that they may withdraw from the 
study at any time, without prejudice. A copy of the informed consent document will be given to the 
participants for their records. The informed consent process will be conducted and documented in the 
source document (including the date), and the form signed, before the participant undergoes any study-
specific procedures. The rights and welfare of the participants will be protected by emphasizing to them 
that the quality of their medical care will not be adversely affected if they decline to participate in this 
study. 
10.1.2 STUDY DISCONTINUATION AND CLOSURE 
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable 
cause.  Written notification, documenting the reason for study suspension or termination, will be 
provided by the suspending or terminating party to study participants, investigator, funding agency, and 
regulatory authorities.  If the study is prematurely terminated or suspended, the Principal Investigator 
(PI) will promptly inform study participants, the Institutional Review Board (IRB), and sponsor and will 
provide the reason(s) for the termination or suspension.  Study participants will be contacted, as 
applicable, and be informed of changes to study visit schedule. 
  
Circumstances that may warrant termination or suspension include, but are not limited to: 
• 
Determination of unexpected, significant, or unacceptable risk to participants  
• 
Insufficient compliance to protocol requirements 
• 
Data that are not sufficiently complete and/or evaluable 
 
Study may resume once concerns about safety, protocol compliance, and data quality are addressed, 
and satisfy the investigators and, IRB. 
 
10.1.3 CONFIDENTIALITY AND PRIVACY  
Participant confidentiality and privacy is strictly held in trust by the investigators and their staff. This 
confidentiality is extended to cover all testing and clinical information. Therefore, the study protocol, 
documentation, data, and all other information generated will be held in strict confidence. All research 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
activities will be conducted in as private a setting as possible. The study participant’s contact 
information will be securely stored at each clinical site for internal use during the study. Electronic study 
data will be stored in secure servers and all paper documents will be filed in locked cabinets. These data 
will be accessible only to the investigators and study personnel. Each participant’s data will be coded 
using a unique identification number and the codes placed in a secure server. Data will be de-identified 
before sharing with any party outside of the study investigators and study personnel. No information 
concerning the study or the data will be released to any unauthorized third party without prior written 
approval of the IRB.  
 
10.1.4 FUTURE USE OF STORED DATA  
Data collected for this study will be analyzed and stored at the Mayo Clinic, Rochester. After the study is 
completed, the de-identified, archived data may be made available for use by other researchers within 
the institution after obtaining IRB approval.  
 
10.1.5 SAFETY OVERSIGHT 
Safety oversight will be under the direction of a Data and Safety Monitoring Board (DSMB) composed of 
one Cardiologist, one Neurologist and a biostatistician outside of the research team. Members of the 
DSMB will be independent from the study conduct and free of conflict of interest, or measures should 
be in place to minimize perceived conflict of interest.  The DSMB will meet at least semiannually to 
assess safety data on each arm of the study. The DSMB will provide its input to the investigator and 
sponsor. 
 
10.1.6 DATA HANDLING AND RECORD KEEPING  
10.1.6.1 DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site 
investigator. The investigator is responsible for ensuring the accuracy, completeness, legibility, and 
timeliness of the data reported. Hardcopies of the study visit worksheets including cognitive function 
battery and baseline clinical characteristics will be the source document worksheets for recording data 
for each participant enrolled in the study.  Data recorded in the electronic case report form (eCRF) 
derived from source documents should be consistent with the data recorded on the source documents. 
Electronic data on clinical characteristics will be stored in RedCap and data on neurocognitive testing will 
be stored in SDMS. Brain MRI images and their interpretation will be served in electronic form in a 
secure server. The data system includes password protection and internal quality checks, such as 
automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate. 
 
10.1.6.2 STUDY RECORDS RETENTION  
 
10.1.7 PROTOCOL DEVIATIONS  
A protocol deviation is any noncompliance with the clinical trial protocol requirements. The 
noncompliance may be either on the part of the participant, the investigator, or the study staff. It is the 
responsibility of the investigator to identify and report deviations. The timing of investigator reporting of 
protocol violation/deviations to the IRB, using the IRB electronic Reportable Event form, is dependent 
on the severity of the protocol violation/deviation. Major protocol violations/deviations that affect the 
rights and welfare of subjects and others, increase risks to subjects and others, decrease potential 
benefits, compromise the integrity or validity of the research; or represent willful or knowing 
misconduct must be reported by the investigator within five working days of becoming aware of the 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
violation/deviation. Minor non-compliance should be summarized and submitted to the IRB at the time 
of continuing review. 
 
Examples of problems or events which may meet the definition of Major Protocol Violations/Deviations 
(non-compliance):  
• Enrolling subjects who did not meet inclusion/exclusion criteria on a greater-than-minimal risk study 
• Performing study procedures not approved by the IRB 
• Performing study procedures before obtaining informed consent 
• Failure to obtain and/or document informed consent 
• Use of an unapproved consent document 
• Changing the protocol without prior IRB approval except when necessary to eliminate immediate harm 
to a subject 
• Breach of confidentiality (i.e. any occurrence of unapproved PHI disclosure) 
• Receipt of incorrect treatment or dose by a subject 
• Loss or destruction of samples or data 
• Over-enrollment of subjects on a greater than minimal risk study 
• Unauthorized (i.e. not IRB approved) persons participating in the conduct of a research study 
 
10.1.8 PUBLICATION AND DATA SHARING POLICY 
 
 
 
 
 
 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
Protocol Amendment History 
The table below is intended to capture changes of IRB-approved versions of the protocol, including a 
description of the change and rationale. A Summary of Changes table for the current amendment is 
located in the Protocol Title Page.  
 
Version 
Date 
Description of Change  
Brief Rationale 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 REFERENCES  

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
 
 
1. 
Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive impairment associated with atrial fibrillation: A 
meta-analysis. Ann Intern Med. 2013;158:338-346 
2. 
Santangeli P, Di Biase L, Bai R, Mohanty S, Pump A, Cereceda Brantes M, Horton R, Burkhardt JD, 
Lakkireddy D, Reddy YM, Casella M, Dello Russo A, Tondo C, Natale A. Atrial fibrillation and the risk of 
incident dementia: A meta-analysis. Heart Rhythm. 2012;9:1761-1768 
3. 
Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS, Anderson JL, Muhlestein JB, Horne BD, Lappe 
DL, Day JD. Atrial fibrillation is independently associated with senile, vascular, and alzheimer's dementia. 
Heart Rhythm. 2010;7:433-437 
4. 
Thacker EL, McKnight B, Psaty BM, Longstreth WT, Jr., Sitlani CM, Dublin S, Arnold AM, Fitzpatrick AL, 
Gottesman RF, Heckbert SR. Atrial fibrillation and cognitive decline: A longitudinal cohort study. 
Neurology. 2013;81:119-125 
5. 
Woods CE, Olgin J. Atrial fibrillation therapy now and in the future: Drugs, biologicals, and ablation. Circ 
Res. 2014;114:1532-1546 
6. 
Kelley AS, McGarry K, Gorges R, Skinner JS. The burden of health care costs for patients with dementia in 
the last 5 years of life. Ann Intern Med. 2015;163:729-736 
7. 
Lip GY, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: A systematic review of the 
epidemiology of atrial fibrillation in regions outside north america and europe. Chest. 2012;142:1489-
1498 
8. 
Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial 
fibrillation in adults: National implications for rhythm management and stroke prevention: The 
anticoagulation and risk factors in atrial fibrillation (atria) study. JAMA. 2001;285:2370-2375 
9. 
Llibre Rodriguez JJ, Ferri CP, Acosta D, Guerra M, Huang Y, Jacob KS, Krishnamoorthy ES, Salas A, Sosa AL, 
Acosta I, Dewey ME, Gaona C, Jotheeswaran AT, Li S, Rodriguez D, Rodriguez G, Kumar PS, Valhuerdi A, 
Prince M, Dementia Research G. Prevalence of dementia in latin america, india, and china: A population-
based cross-sectional survey. Lancet. 2008;372:464-474 
10. 
Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of 
dementia in late life. Neurology. 2005;64:277-281 
11. 
Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: A 
systematic review. Lancet Neurol. 2006;5:64-74 
12. 
Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and 
dementia in a population-based study. The rotterdam study. Stroke; a journal of cerebral circulation. 
1997;28:316-321 
13. 
Kwok CS, Loke YK, Hale R, Potter JF, Myint PK. Atrial fibrillation and incidence of dementia: A systematic 
review and meta-analysis. Neurology. 2011;76:914-922 
14. 
Gaita F, Corsinovi L, Anselmino M, Raimondo C, Pianelli M, Toso E, Bergamasco L, Boffano C, Valentini MC, 
Cesarani F, Scaglione M. Prevalence of silent cerebral ischemia in paroxysmal and persistent atrial 
fibrillation and correlation with cognitive function. J Am Coll Cardiol. 2013;62:1990-1997 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
15. 
Graff-Radford J, Madhavan M, Vemuri P, Rabinstein AA, Cha RH, Mielke MM, Kantarci K, Lowe V, Senjem 
ML, Gunter JL, Knopman DS, Petersen RC, Jack CR, Jr., Roberts RO. Atrial fibrillation, cognitive impairment, 
and neuroimaging. Alzheimers Dement. 2015 
16. 
Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and 
white matter lesions increase stroke risk in the general population: The rotterdam scan study. Stroke. 
2003;34:1126-1129 
17. 
Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the 
risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215-1222 
18. 
Akoudad S, Darweesh SK, Leening MJ, Koudstaal PJ, Hofman A, van der Lugt A, Stricker BH, Ikram MA, 
Vernooij MW. Use of coumarin anticoagulants and cerebral microbleeds in the general population. Stroke. 
2014;45:3436-3439 
19. 
Chatzikonstantinou A, Willmann O, Szabo K, Hennerici MG. Cerebral microbleeds are uncommon in 
ischemic stroke associated with nonvalvular atrial fibrillation. J Neuroimaging. 2011;21:103-107 
20. 
Song TJ, Kim J, Song D, Nam HS, Kim YD, Lee HS, Heo JH. Association of cerebral microbleeds with 
mortality in stroke patients having atrial fibrillation. Neurology. 2014;83:1308-1315 
21. 
Ueno H, Naka H, Ohshita T, Kondo K, Nomura E, Ohtsuki T, Kohriyama T, Wakabayashi S, Matsumoto M. 
Association between cerebral microbleeds on t2*-weighted mr images and recurrent hemorrhagic stroke 
in patients treated with warfarin following ischemic stroke. AJNR Am J Neuroradiol. 2008;29:1483-1486 
22. 
van Etten ES, Auriel E, Haley KE, Ayres AM, Vashkevich A, Schwab KM, Rosand J, Viswanathan A, 
Greenberg SM, Gurol ME. Incidence of symptomatic hemorrhage in patients with lobar microbleeds. 
Stroke. 2014;45:2280-2285 
23. 
Wu Y, Chen T. An up-to-date review on cerebral microbleeds. J Stroke Cerebrovasc Dis. 2016;25:1301-
1306 
24. 
Seo SW, Hwa Lee B, Kim EJ, Chin J, Sun Cho Y, Yoon U, Na DL. Clinical significance of microbleeds in 
subcortical vascular dementia. Stroke. 2007;38:1949-1951 
25. 
van Norden AG, van den Berg HA, de Laat KF, Gons RA, van Dijk EJ, de Leeuw FE. Frontal and temporal 
microbleeds are related to cognitive function: The radboud university nijmegen diffusion tensor and 
magnetic resonance cohort (run dmc) study. Stroke. 2011;42:3382-3386 
26. 
Benedictus MR, Hochart A, Rossi C, Boulouis G, Henon H, van der Flier WM, Cordonnier C. Prognostic 
factors for cognitive decline after intracerebral hemorrhage. Stroke. 2015;46:2773-2778 
27. 
Hu T MM, Gersh BJ, Roger VL, Killian J, Weston SA, Asirvatham SJ, Chamberlain AM. . Lower time in 
therapeutic range on warfarin correlates with incident dementia in patients with atrial fibrillation. Heart 
Rhythm Journal. 2016 
28. 
Jacobs V, Woller SC, Stevens SM, May HT, Bair TL, Crandall BG, Cutler M, Day JD, Weiss JP, Osborn JS, 
Mallender C, Anderson JL, Bunch TJ. Percent time with a supratherapeutic inr in atrial fibrillation patients 
also using an antiplatelet agent is associated with long-term risk of dementia. J Cardiovasc Electrophysiol. 
2015 
29. 
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, 
Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, 
Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, 

Apixaban vs Warfarin in reducing rate of cognitive function decline, silent cerebral infarcts and cerebral microbleeds in atrial 
fibrillation patients 
Version 2.0 
 
 
Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, Committees A, Investigators. Apixaban versus warfarin 
in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992 
30. 
al. MODe. Effect of apixaban on brain infarction and microbleeds: Averroes-mri assessment study. Am 
Heart J. 2016;doi: 10.1016/j.ahj.2016.03.019 
31. 
Jacobs V, May HT, Bair TL, Crandall BG, Cutler MJ, Day JD, Mallender C, Osborn JS, Stevens SM, Weiss JP, 
Woller SC, Bunch TJ. Long-term population-based cerebral ischemic event and cognitive outcomes of 
direct oral anticoagulants compared with warfarin among long-term anticoagulated patients for atrial 
fibrillation. Am J Cardiol. 2016 
32. 
Fumagalli S, Cardini F, Roberts AT, Boni S, Gabbai D, Calvani S, Casalone Rinaldi M, Manetti S, Tarantini F, 
Marchionni N. Psychological effects of treatment with new oral anticoagulants in elderly patients with 
atrial fibrillation: A preliminary report. Aging Clin Exp Res. 2015;27:99-102 
33. 
Ivnik RJ, Smith GE, Lucas JA, Petersen RC, Boeve BF, Kokmen E, Tangalos EG. Testing normal older people 
three or four times at 1- to 2-year intervals: Defining normal variance. Neuropsychology. 1999;13:121-127 
34. 
Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF, Ivnik RJ, Tangalos EG, Petersen RC, 
Rocca WA. The mayo clinic study of aging: Design and sampling, participation, baseline measures and 
sample characteristics. Neuroepidemiology. 2008;30:58-69